0.00
100.00%
-1.90
Schlusskurs vom Vortag:
$1.90
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$131.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-50.39M
KGV:
0.00
EPS:
-1.23
Netto-Cashflow:
$-37.44M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
Atyr Pharma Inc Stock (LIFE) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
858-731-8389
Adresse
3545 John Hopkins Court, Suite 250, San Diego, CA
Atyr Pharma Inc Stock (LIFE) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
2021-05-10 | Eingeleitet | Laidlaw | Buy |
2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-03-04 | Eingeleitet | ROTH Capital | Buy |
2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
2015-12-16 | Eingeleitet | Citigroup | Neutral |
2015-06-01 | Eingeleitet | Citigroup | Buy |
2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (LIFE) Neueste Nachrichten
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1% - MarketBeat
Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily
ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha
Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily
Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News
Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex
Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN
Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World
Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News
Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World
Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World
Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK
aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire
aTyr Pharma to Participate in September Investor Conferences - StockTitan
ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com
Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com
Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex
aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com
aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com
aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com
ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World
Q3 2024 Earnings Forecast for Atyr PHARMA INC Issued By HC Wainwright (NASDAQ:ATYR) - MarketBeat
ATYR’s Stock Market Adventure: 41.84% YTD Growth Amidst Volatility - The InvestChronicle
ATYR (aTyr Pharma) Cash From Discontinued Investing Activit - GuruFocus.com
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - MarketBeat
Atyr PHARMA INC to Post FY2028 Earnings of $4.72 Per Share, HC Wainwright Forecasts (NASDAQ:ATYR) - Defense World
Atyr PHARMA (NASDAQ:ATYR) Receives “Outperform” Rating from Royal Bank of Canada - Defense World
Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results, Beats Expectations By $0.01 EPS - Defense World
Atyr PHARMA (NASDAQ:ATYR) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Piper Sandler maintains Overweight rating on aTyr Pharma shares By Investing.com - Investing.com UK
Atyr Pharma: Q2 Earnings Snapshot - CT Insider
Atyr Pharma: Q2 Earnings Snapshot - Darien Times
Atyr Pharma: Q2 Earnings Snapshot - CTPost
ATYR (aTyr Pharma) Profitability Rank : 1 (As of Mar. 2024) - GuruFocus.com
ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024 - InvestorPlace
Finanzdaten der Atyr Pharma Inc-Aktie (LIFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atyr Pharma Inc-Aktie (LIFE) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
SCHIMMEL PAUL | Director |
Jul 22 '24 |
Buy |
1.74 |
41,052 |
71,500 |
354,075 |
SCHIMMEL PAUL | Director |
Jul 23 '24 |
Buy |
1.82 |
6,648 |
12,075 |
360,723 |
DENYES NANCY | General Counsel |
Jun 05 '24 |
Buy |
1.86 |
5,000 |
9,276 |
22,267 |
COUGHLIN TIMOTHY | Director |
May 30 '24 |
Buy |
1.75 |
50,000 |
87,500 |
56,000 |
Broadfoot Jill Marie | Chief Financial Officer |
May 31 '24 |
Buy |
1.79 |
5,000 |
8,950 |
27,960 |
Shukla Sanjay | President and CEO |
May 31 '24 |
Buy |
1.81 |
20,000 |
36,140 |
136,548 |
Broadfoot Jill Marie | Chief Financial Officer |
Feb 06 '24 |
Sale |
1.69 |
1,590 |
2,687 |
20,821 |
Shukla Sanjay | President and CEO |
Dec 12 '23 |
Buy |
1.18 |
12,000 |
14,136 |
106,173 |
Shukla Sanjay | President and CEO |
Dec 11 '23 |
Buy |
1.17 |
3,000 |
3,510 |
94,173 |
Shukla Sanjay | President and CEO |
Nov 13 '23 |
Buy |
1.11 |
13,578 |
15,085 |
91,173 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):